Funding for this research was provided by:
Text and Data Mining valid from 2019-01-22
Received: 1 October 2018
Accepted: 19 December 2018
First Online: 22 January 2019
Ethics approval and consent to participate
: The study received ethical approval from the institutional review board or independent ethics committee at each site, and written informed consent was obtained from patients before study enrollment.
: Not applicable.
: William B. Young has served on advisory boards for Alder, Allergan, Cipla, Lilly, and Supernus; has consulted for Allergan and Supernus; and has received research support from AGA, Alder, Allergan, Amgen, Autonomic Technology, Cumberland, Dr. Reddy’s Laboratories, Eli Lilly, eNeura, Merz, and St. Jude Medical. J. Ivan Lopez has no disclosures to report. John F. Rothrock has served on advisory boards and/or has consulted for Allergan, Lilly, Amgen, and Supernus. He also has received funding for travel and speaking from Supernus and has received honoraria from Allergan for participating as a speaker and preceptor at Allergan-sponsored educational programs. His parent institution has received funding from Allergan, Amgen, and Dr. Reddy’s Laboratories for clinical research he has conducted. Amelia Orejudos is an employee of Allergan. Aubrey Manack Adams is an employee of Allergan and owns stock in the company. Richard B. Lipton serves on the editorial boards of <i>Neurology</i> and <i>Cephalalgia</i> and as senior advisor to <i>Headache</i>. He has received research support from the National Institutes of Health. He also receives support from the Migraine Research Foundation and the National Headache Foundation. He has reviewed for the National Institute on Aging and National Institute of Neurological Disorders and Stroke, serves as consultant or advisory board member or has received honoraria from Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s Laboratories, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Novartis, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. He receives royalties from <i>Wolff’s Headache</i> (8th Edition, Oxford University Press), Informa, and Wiley. He holds stock options in eNeura Therapeutics and Biohaven. Andrew M. Blumenfeld has served on advisory boards for Allergan, Amgen, Alder, Teva, Supernus, Promius, Egalet, and Lilly and has received funding for speaking from Allergan, Amgen, Pernix, Supernus, Depomed, Avanir, and Promius.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.